This page documents the major contradictions and competing hypotheses in neurodegenerative disease research. Scientific disagreements are a hallmark of active research fields and often drive progress. This synthesis identifies areas where evidence conflicts and maps pathways toward resolution.
¶ Major Contradiction Domains
The Conflict: Whether amyloid-beta (Aβ) or tau pathology is the primary driver of Alzheimer's disease progression [@musachio2021][@jacobs2022].
Recent systematic reviews provide conflicting perspectives on this debate. Suzuki et al. (2024) review the clinical outcomes of both anti-amyloid and anti-tau therapeutic approaches, noting that while amyloid-targeting antibodies reduce plaque burden, clinical benefits remain modest [1]. Meanwhile, Zhang et al. (2024) provide a comprehensive overview of AD mechanisms, emphasizing the complex interplay between multiple pathological pathways [2]. Liu et al. (2024) further update our understanding of diagnostic and therapeutic advances [3].
| Perspective |
Evidence Supporting |
Evidence Challenging |
| Amyloid-Centric (Aβ first) |
Aβ mutations cause FAD; APP duplication causes AD; amyloid antibodies reduce plaques but have modest clinical benefit [@van2024][@saville2024] |
Tau correlates better with cognitive decline; amyloid-lowering trials show limited efficacy [@mintun2021][@bassi2024] |
| Tau-Centric (Tau first) |
Tau NFTs correlate with cognition; tau spread predicts progression [@jacobs2022][@peattie2024] |
Tau mutations don't cause AD; anti-tau trials also show limited benefit |
| Dual Hit (Synergistic) |
Both required for full AD phenotype; evidence of Aβ-tau amplification loop [@musachio2021] |
Mechanism of synergy unclear; therapeutic targeting complex |
Resolution Status: Partial — The Amyloid-Tau Synergistic Hypothesis provides a unified framework, but clinical validation remains incomplete.
The Conflict: Whether the amyloid cascade hypothesis accurately describes AD pathogenesis or needs fundamental revision.
flowchart TD
A["Original Amyloid Cascade<br/>Aβ → Tau → Neuron Loss"] --> B{"Supported?"}
B -->|"Yes"| C["Many Aβ mutations cause FAD"]
B -->|"No"| D["Clinical trials fail"]
E["Modified Amyloid Cascade<br/>Aβ → Inflammation → Tau"] --> F
G["Multiple Hit Models<br/>Aβ + Tau + Inflammation + Other"] --> H
C --> I["Supported by genetics"]
D --> J["Supported by clinical outcomes"]
F --> K["Integrates inflammation"]
H --> L["Most comprehensive"]
Key Contradictions:
- Genetic evidence: APP/PSEN1/PSEN2 mutations → Aβ → FAD (strongly supports) [@selkoe2023]
- Therapeutic evidence: Aβ clearance → modest cognitive benefit (weakens) [@bassi2024][@van2024]
- Biomarker evidence: Aβ elevation precedes tau by 15-20 years (supports timing) [@jacobs2022]
- ARIA risk: Amyloid-related imaging abnormalities complicate treatment [@grimmer2024][@hall2024]
Hypothesis Pages in Conflict:
The Conflict: Whether α-synuclein propagation follows prion-like seeding vs conventional aggregation mechanisms [@prionlike2024][@brundin2024].
Recent reviews have advanced this debate significantly. Burré et al. (2024) outline research priorities for α-synuclein pathogenesis, highlighting the controversy between templated aggregation and conventional mechanisms [14]. Woerman and Bartz (2024) specifically examine host and strain factors that influence prion-like pathogenesis, noting that strain diversity may explain clinical differences between PD and MSA [15]. Leak et al. (2024) provide comprehensive insights into current assumptions about α-synuclein in Lewy body disease [16]. Additionally, Negi et al. (2024) review the broader misfolding mechanisms underlying PD pathogenesis [23].
| Mechanism |
Evidence For |
Evidence Against |
| Prion-Like Seeding |
Template-directed conversion; cell-to-cell transfer; strain variants (PD vs MSA) [@aulicky2023][@conicella2024] |
No confirmed human-to-human transmission; inconsistent strain stability |
| Conventional Aggregation |
Intracellular accumulation; UPS/autophagy involvement |
Doesn't explain spread pattern |
| Hybrid Model |
Both mechanisms operate; context-dependent [@notarstefano2023] |
Mechanistic complexity |
Resolution Status: Evolving — The Prion-Like Propagation Hypothesis page captures the evidence, but consensus on mechanism remains elusive.
The Conflict: Whether microglia primarily protect or damage the brain in neurodegeneration.
This contradiction has been extensively reviewed recently. Heneka et al. (2025) provide a comprehensive update on neuroinflammation in AD, the central role of microglia, and the ongoing debate about whether microglial activation is protective or harmful [10]. Shi and colleagues (2025) review the TREM2-microglia relationship, highlighting how TREM2 variants influence disease risk and microglial function [11]. Zhao et al. (2025) further elaborate on how TREM2 bridges microglia with the extracellular microenvironment and the therapeutic implications [12]. Fan et al. (2024) review emerging microglial biology and potential therapeutic targets [13].
flowchart LR
subgraph Microglial_Roles
A["Microglia"] --> B["Beneficial Functions"]
A --> C["Harmful Functions"]
B --> B1["Aβ Phagocytosis"]
B --> B2["Trophic Support"]
B --> B3["Synaptic Pruning"]
C --> C1["Pro-inflammatory Cytokines"]
C --> C2["NADPH Oxidase ROS"]
C --> C3["Synaptic Stripping"]
end
D["TREM2 Variants"] --> E{"Risk?"}
D --> F{"Risk?"}
E -->|"Yes"| G["DAM: Protective?"]
F -->|"No"| H["Loss: Harmful?"]
Key Contradictions:
- TREM2 R47H increases AD risk → suggests microglial protection is important [@guerreiro2013]
- TREM2 loss reduces Aβ plaques → suggests microglia may be harmful [@parhizkar2019][@masliah2015]
- DAM (Disease-Associated Microglia) appear protective but may cause damage [@kerenshaul2017][@wang2024]
- TREM2 agonist trials ongoing [@simeoni2024]
- Microglial TREM2 modulates neuroinflammation in AD [@chen2023][@liu2024]
Related Pages:
The Conflict: Whether norepinephrine loss from the locus coeruleus (LC) is an early driver or late consequence of AD/PD [@theofilas2023][@braak2022].
Recent reviews have advanced understanding of LC involvement. Nikolenko et al. (2024) comprehensively review the LC-norepinephrine system's spheres of influence in neurodegenerative diseases, discussing both early vulnerability and progressive degeneration [17]. Matt et al. (2024) provide detailed pharmacological perspectives on targeting the noradrenergic system in neurodegeneration [18].
| Perspective |
Evidence |
| Early Driver |
LC degeneration in prodromal AD; norepinephrine modulates microglia; LC norepinephrine regulates Aβ clearance [@theofilas2023][@price2024][@smith2023] |
| Late Consequence |
LC appears intact in early stages; follows dopaminergic loss in PD [@braak2022] |
Resolution: The Locus Coeruleus Degeneration Hypothesis synthesizes both views, suggesting LC may be both early vulnerable and progressively damaged.
The Conflict: Whether P. gingivalis infection is a cause or correlate of Alzheimer's disease [@porphyromonas2023][@dominici2022][@johansson2023].
This debate remains controversial. Cichońska et al. (2024) provide a narrative review of recent aspects connecting periodontitis and AD, noting the correlation vs causation challenge [19]. Plachokova et al. (2024) comprehensively review periodontitis as a potentially modifiable risk factor for neurodegenerative diseases [20].
flowchart TD
A["P. gingivalis in AD Brain"] --> B{"Support for Causation?"}
B -->|"Strong"| C["Gingipains in AD brain<br/>Porphyromonas gingivalis AD hypothesis"]
B -->|"Weak"| D["Correlation only<br/>Confounded by poor oral health in AD"
B -->|"Negative"| E["Phase III trials not completed<br/>Kavain trials negative"]
C --> I["Controversial but active"]
D --> J["Likely correlative"]
E --> K["Weakens causation hypothesis"]
F --> K2["COR388 Phase 2 results pending [@ishida2024]"]
Resolution Status: Unresolved — The Porphyromonas gingivalis AD Hypothesis page details the debate. Recent reviews suggest a correlative rather than causal relationship [19][20].
Different analyses rank ALS mechanisms differently, as reviewed by Sharma et al. (2024) who provide comprehensive insights into genetic underpinnings, pathogenesis, and therapeutic horizons [22]:
| Analysis Method |
Top Ranked Mechanism |
| Genetic evidence |
C9orf72 hexanucleotide expansion [21] |
| Proteinopathy |
TDP-43 aggregation |
| Cellular stress |
RNA processing dysfunction |
| Therapeutic response |
Glutamate excitotoxicity |
The ALS Hypothesis Rankings page captures this variation.
Similarly, PD has multiple competing frameworks, recently reviewed by Hattori and Sato (2024) on mitochondrial dysfunction [21] and Shen and Dettmer (2024) on α-synuclein effects on mitochondrial quality control [22]:
| Domain |
Evidence Strength |
Consensus Level |
Resolution Priority |
| Aβ-Tau relationship |
Strong |
Medium |
High |
| Prion-like propagation |
Moderate |
Low |
High |
| Microglial duality |
Moderate |
Low |
Medium |
| LC involvement |
Moderate |
Medium |
Medium |
| P. gingivalis role |
Weak |
Very Low |
Low |
-
Unified Amyloid-Tau-Targeting Strategy
- Question: Can combined Aβ and tau targeting achieve synergistic benefits?
- Current gap: No trials have tested combination therapy rigorously [@cummings2024]
-
Microglial State Transitions
- Question: What determines whether microglia adopt protective vs harmful states?
- Current gap: Single-cell sequencing data needs integration [@chen2023]
-
Strain-Specific Alpha-Synuclein
- Question: Do different α-syn strains explain PD vs MSA clinical differences?
- Current gap: No robust strain classification system [@aulicky2023][@conicella2024]
-
Norepinephrine Modulation
- Question: Can LC-targeted therapy slow neurodegeneration?
- Current gap: No selective norepinephrine reuptake inhibitors in AD trials [@price2024]
¶ Synthesis and Next Steps
- Mechanistic integration: Most hypotheses operate in isolation
- Temporal dynamics: How mechanisms interact over disease progression
- Multi-marker validation: No consensus on biomarker combinations to test hypotheses
- Therapeutic translation: Hypothesis ranking doesn't predict therapeutic success
flowchart TD
A["Contradiction Resolution Framework"] --> B1["Define testable predictions"]
A --> B2["Design crucial experiments"]
A --> B3["Establish biomarker correlates"]
A --> B4["Prioritize therapeutic targets"]
B1 --> C1["Aβ-Tau: Sequential vs simultaneous targeting"]
B2 --> C2["α-Syn strains: Patient-derived models"]
B3 --> C3["Microglial states: PET ligands for DAM"]
B4 --> C4["LC: Norepinephrine PET + challenge studies"]
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Unknown (n.d.)
- Suzuki et al., Anti-amyloid-beta Antibodies and Anti-tau Therapies for Alzheimer's Disease (2024)
- Zhang et al., Recent advances in Alzheimer's disease (2024)
- Liu et al., Updates in Alzheimer's disease (2024)
- Amyloid, Tau, and Neurodegeneration in Alzheimer's Disease (2024)
- TREM2 in Alzheimer's Disease (2023)
- Alpha-Synuclein Strains in Parkinson's Disease (2024)
- Locus Coeruleus in Alzheimer's Disease (2023)
- Porphyromonas gingivalis and Alzheimer's Disease: A Critical Review (2023)
- Disease-Associated Microglia: A Unifying Concept for Neurodegeneration (2024)
- Heneka et al., Neuroinflammation in Alzheimer disease (2025)
- Shi et al., Microglia, Trem2, and Neurodegeneration (2025)
- Zhao et al., TREM2 bridges microglia and extracellular microenvironment (2025)
- Fan et al., Emerging microglial biology highlights potential therapeutic targets for Alzheimer's disease (2024)
- Burré et al., Research Priorities on the Role of alpha-Synuclein in Parkinson's Disease Pathogenesis (2024)
- Woerman & Bartz, Effect of host and strain factors on alpha-synuclein prion pathogenesis (2024)
- Leak et al., Current insights and assumptions on alpha-synuclein in Lewy body disease (2024)
- Nikolenko et al., Locus Coeruleus-Norepinephrine System: Spheres of Influence (2024)
- Matt et al., Locus Coeruleus and Noradrenergic Pharmacology in Neurodegenerative Disease (2024)
- Cichońska et al., Recent Aspects of Periodontitis and Alzheimer's Disease (2024)
- Plachokova et al., Periodontitis: A Plausible Modifiable Risk Factor for Neurodegenerative Diseases (2024)
- Geng & Cai, Role of C9orf72 hexanucleotide repeat expansions in ALS/FTD pathogenesis (2024)
- Sharma et al., Unraveling the multifaceted insights into amyotrophic lateral sclerosis (2024)
- Hattori & Sato, Mitochondrial dysfunction in Parkinson's disease (2024)
- Shen & Dettmer, Alpha-Synuclein Effects on Mitochondrial Quality Control in Parkinson's Disease (2024)
- Negi et al., The misfolding mystery: alpha-synuclein and the pathogenesis of Parkinson's disease (2024)
- Selkoe et al., Alzheimer Disease: A Conceptual Overview and Therapeutic Directions (2023)
- Bassi et al., Failure of Anti-Amyloid Therapies in Alzheimer's Disease (2024)
- Jacobs et al., Tau PET Correlates with Cognitive Decline in Alzheimer's Disease (2022)
- Musachio et al., The Amyloid-Tau Synergistic Relationship in Alzheimer's Disease (2021)
- Brundin et al., Prion-Like Alpha-Synuclein Propagation in Parkinson's Disease (2024)
- Menge et al., Alpha-Synuclein Strains and Seed Amplification Assays (2023)
- Hansen et al., TREM2 in Alzheimer's Disease Clinical Development (2024)
- Kerenshaul et al., A Unique Microglia Type Associated with Alzheimer's Disease (2017)
- Deczkowska et al., TREM2 Physiology and Pathology (2020)
- Wang et al., Microglial Activation in Alzheimer's Disease: TREM2-Dependent Responses (2020)
- Schlepckow et al., Enhancing Protective Microglial Activities with a TREM2 Agonist (2020)
- Theofilas et al., Locus Coeruleus Degeneration Predates Clinical Symptoms in AD (2023)
- Braak et al., Locus Coeruleus alpha-Synuclein Pathology in Parkinson's Disease (2022)
- Manchester et al., Norepinephrine Modulation of Microglia in Neurodegeneration (2024)
- Dominici et al., Porphyromonas gingivalis in Alzheimer's Disease: Evidence and Limitations (2022)
- Chen et al., Gingipain Inhibitors for Alzheimer's Disease: Clinical Trial Status (2024)
- Guerreiro et al., TREM2 Variants in Alzheimer's Disease (2013)
- Parhizkar et al., Loss of TREM2 Function Increases Amyloid Severity (2019)